IGF-1 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-12-09. Numbers and descriptions here follow the published literature rather than marketing material.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Fragment analog of human growth hormone |
| Sequence basis | hGH 176–191 region | Modified C-terminal fragment |
| Common synonyms | AOD-9604; AOD9604; hGH fragment | Research and trade names vary |
| Regulatory status | Not approved as a drug | Prohibited in competitive sport |
| Research code | AOD9604 | Used in scientific and patent literature |
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
phenylacetaldehyde methyl salicylate 2-phenylethanol benzaldehyde benzyl alcohol benzyl acetate methyl-2-methoxy benzoate Although the strongest attractor is phenylacetaldehyde, the cabbage looper is more attracted to a blend of odors than phenylacetaldehyde alone.
== Company history == BIA Separations was formed in 1998 by a group of scientists in Ljubljana, Slovenia to commercialize a new chromatographic resin based on monolith technology. Monolithic resin was developed independently by three different laboratories in late 1980s led by Hjertén, Švec and Tennikova. The company was one of the few Slovenian companies to receive venture capital funding at that time-Horizonte Venture Management realizing the potential of monoliths made the initial investment in the company. During that year, BIA Separations released its first commercial product marketed under the trade name of CIM (Convective Interaction Media). The new technique was named HPMC (High Performance Monolith Chromatography). During the 1999 and 2000s, the company promoted this new platform technology to the scientific and business community and registered several patents. In 2007 the company headquarters moved to Villach, Austria. In 2011 BIA Separations entered a strategic partnership with Japan Synthetic Rubber Corporation, a Japanese company producing synthetic materials. A strategic partnership agreement with Showa Denko K.K. (SDK) was signed in 2012.
10 November Dead Men Talk, new dating techniques reveal more about the evolution of man, found from the Skhul and Qafzeh hominins at the Qafzeh cave, and future DNA sequencing methods could reveal from bones how man evolved, it featured Milford H. Wolpoff and Chris Stringer, being similar to the September 1996 edition about Neanderthals; a cave object was thought to be 40,000 years ago, but now was thought to be 100,000 years old; there were two paradigms, one where everyone is from Homo Erectus, and the other where Homo Sapiens evolved exclusively in Africa from Homo Erectus; this theory was from evidence at Border Cave in South Africa, Omo Kibish Formation in Ethiopia, and the Skhul cave; Milford Wolpoff, of the University of Michigan, supported the first multi-regional model; the second Eve theory came from Chris Stringer of the Natural History Museum, who looked at a fossil at Jebel Irhoud, Morocco; new dating techniques were electron spin resonance dating (ESR), deployed by Dr Rainer Grün at the Godwin Laboratory, University of Cambridge, and thermoluminescence dating (TL) which looked at flints that had been heated in primitive fires; a Neanderthal at Kebara Cave was dated at 60,000, with the new dating technique; the two caves, Skhul had homo sapiens, and Tanum Cave had Neanderthals, nearby; Chris Stringer thought that the Neanderthals split 300,000 years ago; the Neanderthal found at Amud Cave had a large brain; Joel Rak of Tel Aviv University believed that Neanderthals were a separate species; geneticist Rebecca L.
=== Laboratory preparation === Rarely is there any interest in the synthesis of alkanes, since they are usually commercially available and less valued than virtually any precursor. The best-known method is hydrogenation of alkenes. Many C−X bonds can be converted to C−H bonds using lithium aluminium hydride, Clemmenson reduction, and other specialized routes. Hydrolysis of alkyl Grignard reagents and alkyl organolithium reagents gives alkanes.
Sources: en.wikipedia.org
The first three prize winners at the late coursing meeting at Great Bend were trained on Spratt's Patent Dog Biscuit. This same dog food won no less than three awards, including a gold medal, at the Exposition in Paris which has just closed. It would seem that the decision of the judges is more than backed up by the result in the kennel. Another good dog food is that manufactured by Austin & Graves, of Boston. They, too, seem to be meeting with great success in their line. Canned horse meat was introduced in the United States under the Ken-L Ration brand after World War I as a means to dispose of excess horses no longer needed for the war. The 1930s saw the introduction of canned cat food and dry meat-meal dog food by the Gaines Food Co. By the time World War II ended, pet food sales had reached $200 million. In the 1950s Spratt's became part of General Mills. For companies such as Nabisco, Quaker Oats, and General Foods, pet food represented an opportunity to market by-products as a profitable source of income.
=== Carotenosis === Carotenoderma, also referred to as carotenemia, is a benign and reversible medical condition where an excess of dietary carotenoids results in orange discoloration of the outermost skin layer. It is associated with a high blood β-carotene value. This can occur after a month or two of consumption of beta-carotene rich foods, such as carrots, carrot juice, tangerine juice, mangos, or in Africa, red palm oil. β-carotene dietary supplements can have the same effect. The discoloration extends to palms and soles of feet, but not to the white of the eye, which helps distinguish the condition from jaundice. Carotenodermia is reversible upon cessation of excessive intake. Consumption of greater than 30 mg/day for a prolonged period has been confirmed as leading to carotenemia.
==== Inverted burial ==== For humans, maintaining an upside-down position, with the head vertically below the feet, is highly uncomfortable for any extended period of time, and consequently burial in that attitude (as opposed to attitudes of rest or watchfulness, as above) is highly unusual and generally symbolic. Occasionally suicides and assassins were buried upside down, as a post-mortem punishment and (as with burial at cross-roads) to inhibit the activities of the resulting undead. In Gulliver's Travels, the Lilliputians buried their dead upside down:
Sources: en.wikipedia.org
Hyperforin is a phytochemical produced by some of the members of the plant genus Hypericum, notably Hypericum perforatum (St John's wort). Hyperforin may be involved in the pharmacological effects of St. John's wort, specifically in its antidepressant effects. Meta-analyses of clinical trials suggest that H. perforatum is as effective as SSRIs for treating mild to moderate depression and is better tolerated, although findings are limited by short study durations. Hyperforin is found in significant amounts only in H. perforatum, where it accumulates as a probable plant defense compound, with modern carbon dioxide extraction methods used to isolate it from mixtures containing related compounds like adhyperforin.
== Further reading == Bailey, Ronald (2012). Half of The Facts You Know Are Probably Wrong, a review of Samuel Arbesman's book on Reason.com Global Summit 2006: Technology Connected Futures. Connectivism: Learning and Knowledge Today by George Siemens Babbage (2012). The Half Life of Facts, The Economist. A Q&A with Samuel Arbesman. Machlup, F. (1962). Knowledge production and distribution in the United States. Princeton, NJ: Princeton University Press. Samuel Arbesman (2012). The Half-life of Facts: Why Everything We Know Has an Expiration Date. Current Hardcover. ISBN 978-1-59184-472-3. Farnam Street Media Inc. (2018). https://fs.blog/2018/03/half-life/
The "vagusstuff" (as Loewi called it) causing the myotropic (muscle enhancing) effects was later identified to be acetylcholine and norepinephrine. Loewi won the Nobel Prize for his discovery. Recent work in endocrinology focuses on the molecular mechanisms responsible for triggering the effects of hormones. The first example of such work being done was in 1962 by Earl Sutherland. Sutherland investigated whether hormones enter cells to evoke action, or stayed outside of cells. He studied norepinephrine, which acts on the liver to convert glycogen into glucose via the activation of the phosphorylase enzyme. He homogenized the liver into a membrane fraction and soluble fraction (phosphorylase is soluble), added norepinephrine to the membrane fraction, extracted its soluble products, and added them to the first soluble fraction. Phosphorylase activated, indicating that norepinephrine's target receptor was on the cell membrane, not located intracellularly. He later identified the compound as cyclic AMP (cAMP) and with his discovery created the concept of second-messenger-mediated pathways. He, like Loewi, won the Nobel Prize for his groundbreaking work in endocrinology.
Sources: en.wikipedia.org
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.
It was investigated in clinical trials for obesity, but it did not receive approval for that use in major markets. Results were generally modest or mixed, and it remains an experimental compound.
WADA lists it as a prohibited peptide hormone. Its use can be detected by laboratory methods, and athletes are subject to sanctions if it is found in samples.
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.